Myocardial protection of MCI-186 in rabbit ischemia-reperfusion
Publication in refereed journal

Times Cited
Web of Science102WOS source URL (as at 19/10/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractWe observed that 3-methyl-1-1-phenyl-2-pyrazolin-5-one (MCI-186), a newly-developed free radical scavenger, attenuated necrosis in the in vivo rabbit hearts upon reperfusion after prolonged ischemia. In rabbits undergoing I hour ligation of the anterior ventricular coronary artery, a single bolus injection of MCI-186 (1.5 mg/kg) was introduced into the post-ischemic heart immediately before 4 hour reperfusion. Compared to negligible necrosis in sham-operated control animals and 33.81 +/- 13.50% necrosis in the area at risk for the saline control group (n = 8), the MCI-186 - treated group (n = 8) had a necrosis of 13.27 +/- 4.60% (p < 0.05 vs saline control group). The pressure-rate index had a slight decrease in MCI-186 treated group compared to the control group (p > 0.05). However, the blood levels of malondialdehyde (MDA) in MCI-186 treated group (2.08 +/- 0.23 muM) was significantly smaller than that of 2.65 +/- 0.31 muM in control animals (p < 0.01), while sham control had an average MDA level of 1.91 +/- 0.40 muM, with p > 0.05 relative to that in the MCI-186 treated group. These data support our contention that MCI-186 reduces reperfusion injury in perfused hearts with prolonged ischemia and the mechanism for the in vivo efficacy of MCI-186 is predominantly related to its antioxidant activities. (C) 2002 Published by Elsevier Science Inc.
All Author(s) ListWu TW, Zeng LH, Wu J, Fung KP
Journal nameLife Sciences
Volume Number71
Issue Number19
Pages2249 - 2255
LanguagesEnglish-United Kingdom
Keywordsheart; ischemia-reperfusion; MCI-186; MDA
Web of Science Subject CategoriesMedicine, Research & Experimental; MEDICINE, RESEARCH & EXPERIMENTAL; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY; Research & Experimental Medicine

Last updated on 2020-20-10 at 02:47